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Abstract A rapid and sensitive method was developed for
the simultaneous determination of fluoxetine and its pri-
mary metabolite, norfluoxetine, in plasma. It was based on
a column-switching approach with a precolumn packed
with large size particles coupled with a liquid chromatog-
raphy–electrospray ionisation–mass spectrometry (LC-
ESI-MS). After a simple centrifugation, plasma samples
were directly injected onto the precolumn. The endoge-
nous material was excluded thanks to a high flow rate
while analytes were retained by hydrophobic interactions.
Afterwards, the target compounds were eluted in back
flush mode to an octadecyl analytical column and de-
tected by ESI-MS. The overall analysis time per sample,
from plasma sample preparation to data acquisition, was
achieved in less than 4 min. Method performances were
evaluated. The method showed good linearity in the range
of 25–1000 ng mL–1 with a determination coefficient higher
than 0.99. Limits of quantification were estimated at 25 ng
mL–1 for fluoxetine and norfluoxetine. Moreover, method
precision was better than 6% in the studied concentration
range. These results demonstrated that the method could be
used to quantify target compounds. Finally, the developed
assay proved to be suitable for the simultaneous analysis
of fluoxetine and its metabolite in real plasma samples.
Keywords Fluoxetine · Norfluoxetine · 
Column-switching · On-line sample preparation · Large
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Introduction
Fluoxetine is an antidepressant for oral administration and
belongs to the selective serotonin reuptake inhibitor (SSRI)
family [1, 2]. It is used to treat depression, bulimia and
obsessive-compulsive disorders. Through N-demethylation,
fluoxetine is extensively metabolised in the liver to nor-
fluoxetine, which is also a potent SSRI and even higher
than of the parent drug. After oral administration, fluox-
etine is rapidly absorbed and disappears from plasma with
a half time of 1–3 days, while norfluoxetine plasma half
time is between 7 and 15 days. Therefore, because of its
increasing popularity and important role in modern ther-
apy, reliable analytical methods for monitoring fluoxetine
and its primary active metabolite in biological fluids are
highly desirable. The chemical structures of fluoxetine, nor-
fluoxetine and methylfluoxetine, which is used as internal
standard (I.S.), are reported in Fig. 1.
Several methods have been reported for the simultane-
ous determination of fluoxetine and its metabolite in bio-
logical fluids. Gas chromatography coupled with electron
capture detection (ECD) [3], nitrogen phosphorus detec-
tion (NPD) [4, 5] or mass spectrometry detection (MS) [6,
7, 8] has been described for the analysis of the studied
compounds. In recent years, aqueous and non-aqueous cap-
illary electrophoresis methods have been developed for the
determination of fluoxetine and other related compounds,
including metabolites, by-products and impurities [9, 10].
Nevertheless, the most widely used method is by far liq-
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Fig. 1 Chemical structures of fluoxetine, norfluoxetine and methyl-
fluoxetine
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uid chromatography (LC) with ultraviolet [11, 12, 13, 14,
15, 16, 17] or fluorescence detection [12, 18. 19, 20]. In
order to achieve high sensitivity, several approaches in-
cluding a preconcentration step [11, 12, 15, 16, 17, 18],
large injection volume [15, 16], derivatisation procedures
[21] or the use of more specific and sensitive detectors such
as mass spectrometry (MS or MS/MS) [22, 23] were found
necessary. More recently, column miniaturisation has evolved
as a very suitable alternative for sensitivity improvement
[24]. Indeed, reducing the column internal diameter in-
creases sensitivity by decreasing chromatographic dilu-
tion [25, 26]. Nevertheless, a sample preparation step is
often required to allow the separation of analytes of inter-
est from endogenous compounds such as salts, lipids and
proteins. The conventional treatment procedures are liq-
uid–liquid extraction (LLE), solid phase extraction (SPE)
or protein precipitation, but these are recognised as labour
intensive and time consuming. Therefore, to achieve fast
analysis, new extraction methods have been developed al-
lowing the direct injection of biofluids in the analytical
system. Among the different strategies applied, the use of
supports with large particles size has received wide ac-
ceptance [27, 28, 29, 30, 31, 32, 33, 34, 35, 36]. Quinn
and Takarewski introduced this concept under the name of
turbulent flow chromatography [37]. Indeed, high flow
rates can be used without excessive back pressure and, there-
fore, the extraction time is considerably reduced. This fast
and generic extraction procedure is based on the rapid
elimination of endogenous components such as proteins
while analytes are retained by hydrophobic interactions
[38]. Afterwards, the target compounds can be eluted with
an organic solvent (acetonitrile or methanol) towards a
specific MS detector (single column approach) or an ana-
lytical column (column-switching approach). Single col-
umn methods have been developed for the direct determi-
nation of drugs and their metabolites, with a short overall
analysis time, generally less than 2 min [28, 39, 40]. How-
ever, due to the low resolution afforded by the large parti-
cle supports, the lack of chromatographic separation can
become a real problem, especially for complex matrices
such as biological fluids. Indeed, despite the high MS de-
tector specificity, it has been demonstrated that, in the bio-
analytical field, the separation remains essential to avoid
or reduce matrix ionisation suppression [35, 36, 41]. There-
fore, an extraction support coupled on-line with an analyt-
ical column (i.e. column-switching set-up) is highly rec-
ommended.
In the present investigation, a fast, selective and highly
sensitive bioanalytical method was developed for the si-
multaneous quantitation of fluoxetine and its primary
metabolite, norfluoxetine, in plasma with a column-switch-
ing system. The method was based on the solid phase ex-
traction of a biological sample onto a stationary phase con-
taining large particles coupled on-line with an LC-electro-
spray ionisation-mass spectrometer detector (ESI-MS).
Method performances were evaluated according to ICH
recommendations [42] and, the method was applied for
the analysis of fluoxetine and its metabolite in real plasma
samples.
Experimental
Chemicals
Fluoxetine and methylfluoxetine hydrochlorides were kindly do-
nated by Heumann Pharma (Nürnberg, Germany). Norfluoxetine
was purchased from Sigma (Buchs, Switzerland). All reagents and
solvents were of analytical grade. Acetonitrile and formic acid
were obtained from SDS (Peypin, France) and ultra-pure water
was supplied by a Milli-Q Gradient A10 water purification unit
from Millipore (Bedford, MA, USA). Blank plasma was obtained
from the blood centre of the Geneva hospital (Geneva, Switzer-
land).
Sample preparation
Stock standard solutions of fluoxetine, norfluoxetine and methyl-
fluoxetine were prepared in acetonitrile at a concentration of 
1000 µg mL–1. Stock solutions were stored at 4 °C. Fluoxetine and
norfluoxetine spiking solutions of 10, 1 and 0.1 µg mL–1 were pre-
pared by further dilution of each stock solution with water. A so-
lution of 1 µg mL–1 of methylfluoxetine in water was prepared by
successive dilution of the stock solution. Calibration samples were
obtained by appropriate dilution of the spiking solutions in blank
plasma to reach a concentration range of 25–1000 µg mL–1. Cali-
bration samples (25, 50, 100, 250, 500, 750 and 1000 ng mL–1) were
prepared extemporaneously for each chromatographic sequence.
Calibration curves were based on the peak area ratio of each com-
pound versus the internal standard. Linearity was assessed by un-
weighted least-squares regression analysis. Using the same proce-
dure, four quality control (QC) plasma samples at 25, 50, 250 and
750 ng mL–1 were prepared and analysed to determine method pre-
cision and accuracy.
Spiked plasma was vortex mixed and diluted 1:1 with the solu-
tion of 1 µg mL–1 of IS (final concentration of IS 500 ng mL–1). Af-
ter vortex mixing, samples were centrifuged for 5 min at 6000 g.
Finally, 50 µL of supernatant was injected in the analytical system.
Patient plasma
Plasma samples were obtained from patients treated with fluox-
etine and were provided by Dr C. Eap of the Biochemistry and Clin-
ical Psychopharmacology Department (Lausanne, Switzerland).
Fluoxetine was administered orally with a daily dose range between
20 and 180 mg. Samples were kept in a freezer at –20 °C until analy-
sis. Each plasma sample was prepared according to the procedure
described in the previous section.
Instrumentation
The configuration of the column-switching system is schemati-
cally shown in Fig. 2. It included an Agilent Series 1100 LC sys-
tem (Agilent Technologies, Walbronn, Germany) equipped with an
autosampler, a binary pump (pump 1), a six-port switching valve
and a single wavelength UV detector. An additional Agilent Series
1100 LC isocratic pump (pump 2) was included in the system. The
Chemstation software suite (Agilent Technologies) was used for
instrument control, data acquisition and data handling. The on-line
sample extraction was performed on an Oasis HLB precolumn
(50×1 mm I.D., dp 30 µm) from Waters Corp. (Milford, MA, USA).
An in-line filter was placed prior to the precolumn to eliminate
particles, which might remain in the sample after the centrifuga-
tion step. The analytical column used for analyte separation was a
Discovery HS C18 (50×2.1 mm I.D., dp 3 µm) from Supelco (Belle-
fonte, PA, USA). The detection was carried out with an Agilent Se-
ries 1100 MSD single quadrupole (Agilent Technologies) equipped
with an orthogonal electrospray ionisation interface. Nitrogen was
used both as nebulising gas at a pressure of 35 psi (1 psi=6894.76 Pa),
and as drying gas at a temperature of 350 °C and a flow rate of 
10 L min–1. Electrospray voltage was set at 3000 V and skimmer
voltage optimised at 40 V. MS detection was carried out in the se-
lected ion-monitoring mode for the protonated molecular ion. The
selected masses were acquired with a dwell time of 392 ms on each
mass to charge ratio, which were 296 for norfluoxetine, 310 for
fluoxetine and 324 for methylfluoxetine.
Analytical conditions
The analytical process involves three main steps: (1) extraction,
(2) analytes transfer and (3) separation.
Extraction step
During the extraction, the switching valve was in position A (Fig. 2).
The autosampler and pump 1 were used to load 50 µL of treated
plasma onto the extraction precolumn. The loading mobile phase
consisted of water-acetonitrile (95:5 v/v) containing 0.1% formic
acid and the flow rate was set at 4 mL min–1. Elution of the en-
dogenous material was monitored by UV detection at 280 nm. Si-
multaneously, the octadecyl analytical column was conditioned
with water-acetonitrile (65:35 v/v) containing 0.1% formic acid
delivered by pump 2 at a flow rate of 400 µL min–1.
Transfer step
After sample extraction (t=0.4 min), the valve was switched to po-
sition B (Fig. 2). Analytes were rapidly eluted from the extraction
support in the back flush mode with the mobile phase and flow rate
reported previously, and transferred to the analytical column for 
1 min.
Separation, wash and re-equilibration step
After sample transfer (t=1.4 min), the valve was switched to its ini-
tial position (position A in Fig. 2). Analytes were separated onto
the analytical column and detected by ESI-MS. Simultaneously,
the precolumn was washed with water-acetonitrile (20:80 v/v) con-
taining 0.1% formic acid delivered by pump 1 at a flow rate of 
4 mL min–1 for 2.5 min. At t=2.9 min, the mobile phase described
for the extraction step at the same flow rate was used to re-equili-
brate the extraction precolumn for 2 min and the system was ready
for the next injection of plasma sample.
Results and discussion
The aim of the present work was to determine fluoxetine
and its primary metabolite in plasma without laborious
sample preparation. Zhu et al. developed a LC-MS-MS
method for determining paroxetine in human plasma with
fluoxetine as internal standard [43]. The analysis was per-
formed in less than 2 min with a sub ng mL–1 limit of quan-
tification (LOQ). However, the sample preparation proce-
dure was based on a conventional liquid–liquid extraction
which represented the time-consuming step of the whole
analytical process. In this work, the potential of the on-
line extraction using a large particle size support coupled
to a LC-MS was investigated to reduce the sample prepa-
ration step in terms of time and sample handling. For this
purpose, the use of large particle supports of hydrophobic
polymer (i.e. dp of 30 to 50 µm) was found to be a suitable
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Fig. 2 Column-switching configuration. A Extraction, precolumn
wash and re-equilibration steps. B Transfer step
Fig. 3 Endogenous elution profile after injection of 50 µL of plasma
diluted 1:1 with water. Detection: UV at 280 nm. Mobile phase:
water-acetonitrile (95:5 v/v) with 0.1% formic acid. Flow rate: 
4 mL min–1
approach allowing the direct injection of biological fluids
in a column-switching configuration. Indeed, this extrac-
tion sorbent enabled a fast and efficient separation of ana-
lytes from endogenous material. The extraction process
was based on the direct injection of biological fluids onto
the support with an aqueous mobile phase at a high flow
rate without generating excessive backpressure. In order to
prevent system clogging, the plasma sample was centrifuged
prior to injection. The high flow rate allowed the rapid pas-
sage of proteins and other endogenous materials through
the support while analytes of interest were retained by
means of hydrophobic interactions. The time needed for
the washout of endogenous material was monitored by UV
detection (280 nm). For 50 µL of plasma diluted 1:1 with
water and injected onto the extraction support, endoge-
nous components were eluted in 0.4 min at a flow rate of
4 mL min–1 (Fig. 3). In these conditions, the breakthrough
volume of fluoxetine, norfluoxetine and methylfluoxetine was
evaluated and no analyte elution was observed for 10 min
(data not shown). Therefore, under these sample loading
conditions, the valve can be switched after 0.4 min. After-
wards, analytes can be eluted from the precolumn to the
analytical column and subjected to a chromatographic
separation with a hydro-organic solvent.
The mobile phase used for analytes transfer and sepa-
ration was water–acetonitrile (65:35 v/v) containing 0.1%
formic acid. This composition was a good compromise
between a satisfactory chromatographic separation and a
short transfer time. Oasis HLB was selected as extraction
material because it presents hydrophobic and hydrophilic
properties. Therefore, the use of a hydrophobic octadecyl
stationary phase for analyte separation allowed a fast ana-
lytes transfer from the extraction support to the analytical
column; which reduced the peak broadening. The transfer
was carried out in backflush mode and the time required
for complete elution of the analytes from the precolumn to
the analytical column was 1 min. At t=1.4 min the valve
was switched back to its original position to ensure pre-
column washing and re-equilibration. According to our
preliminary experiments, a washing step was found nec-
essary to avoid fluoxetine and norfluoxetine carry-over be-
tween successive runs. In this context, a precolumn wash-
ing step with 80% acetonitrile was found sufficient to sup-
press any carry-over. This step was performed simultane-
ously with the chromatographic separation in order to re-
duce the overall analysis time. Under these conditions,
norfluoxetine, fluoxetine and methylfluoxetine were eluted
at 1.71, 1.89 and 2.06 min, respectively, as illustrated in
Fig. 4. Consequently, the total analysis time was less than
4 min.
Repeatability, linearity, sensitivity and accuracy were
assessed to evaluate the developed method. Moreover, to
establish the response function, seven standard solutions,
over a concentration range from 25 to 1000 ng mL–1, were
injected. This range corresponded to the expected concen-
tration found in plasma samples of patients treated with
fluoxetine. Linear regression curves were calculated by
plotting peak area ratio versus concentration, using the least
squares method. The following equations were obtained:
where y represents the peak area ratio, x the solution con-
centration (ng mL–1) and R2 indicates the determination
coefficient. The intercepts were not statistically different
from zero (Student t test, α=0.05) and determination coef-
ficient (R2) values were higher than 0.99 for both analytes.
Method repeatability was expressed in terms of relative
standard deviation and was evaluated by means of quality
control samples (QC) at four concentration levels: 25, 50,
250 and 750 ng mL–1. Accuracy was determined by recal-
culating the four concentration levels using the corre-
sponding response function. Both accuracy and RSD val-
ues are reported in Table 1 and results were satisfactory.
RSD never exceeded 6% at any of the tested concentra-
tions, indicating good method precision.
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Table 1 Accuracy and repeatability values (k=4, n=3)a
Concentration Accuracy Repeatability
(ng ml–1) (%) (CV%)
Fluoxetine 25 105.5 5.1
Norfluoxetine 103.4 1.4
Fluoxetine 50 103.0 2.2
Norfluoxetine 101.3 2.4
Fluoxetine 250 103.3 1.3
Norfluoxetine 104.5 2.6
Fluoxetine 750 104.2 2.0
Norfluoxetine 101.4 2.0
ak=number of concentrations, n=number of plasma samples from
different individuals
CV coefficient of variation
Fig. 4 Chromatograms in SIM mode of spiked plasma at 500 ng mL–1
of fluoxetine and norfluoxetine and at 1000 ng mL–1 of methylflu-
oxetine. Analytical conditions as described in the experimental
section. Abund corresponds to abundance in arbitrary units
The LOQ were determined as being the lowest point
on the standard curve with accuracy and repeatability val-
ues including ±20%. For both compounds, the lower ana-
lyte concentration of the calibration range was 25 ng mL–1.
At this level, accuracy and precision data were below
100±20% and 20% CV, respectively. If necessary, a lower
LOQ could be easy determined. For both compounds, the
LOQ value was estimated at 25 ng mL–1. The method se-
lectivity was assessed by analysing three blank plasma com-
ing from three different sources and no interference was
observed on the chromatograms (data not shown). No sig-
nificant performance degradation of the extraction and an-
alytical columns was observed after the injection of 100
plasma samples (ca. 5 mL of plasma).
The developed method was applied to real samples
from patients receiving daily various fluoxetine doses. A
typical plasma chromatogram from a patient treated with
60 mg of fluoxetine per day is represented in Fig. 5. As il-
lustrated, fluoxetine and its primary metabolite were
clearly detected at 1.7 and 1.9 min. Plasma concentrations,
determined by means of the previously obtained calibra-
tion, were 526 and 180 ng mL–1 for fluoxetine and norflu-
oxetine, respectively. These preliminary results suggest
that the described assay represents a suitable approach for
the therapeutic drug monitoring (TDM) of these pharma-
ceutical compounds in biological fluids.
Conclusion
A rapid and sensitive method with a column-switching
approach using a large particle extraction support coupled
to an LC-MS system was developed for the direct analy-
sis of fluoxetine and its primary metabolite, norfluoxetine,
in plasma samples. Under the optimised conditions, target
analytes were extracted and separated in less than 4 min,
which represents a drastic reduction of the overall analy-
sis time in comparison with commonly used methods.
Thus, with the described system, up to 360 samples per
day can be analysed with minimal manual intervention.
The method showed good performances in terms of accu-
racy and precision. Moreover, the high sensitivity allowed
the determination of fluoxetine and its metabolite at low
ng mL–1 range. In comparison to conventional methods, this
procedure represents a significant improvement in terms
of labour time saving and allows repeated injection onto
the same precolumn. Furthermore, with this automated
on-line sample extraction, the manipulation of hazardous
biological samples is largely reduced.
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